Publication: 3067

Publication: 3067

A phase II multi-center study of the addition of azacitidine to reduced-intensity conditioning allogeneic transplantation for high-risk myelodysplasia (and older patients with acute myeloid leukemia: CALGB 100801 (Alliance)

PubMed

PMC

QxMD

DOI

Google Scholar

Citation:: Biol Blood Marrow Transplant vol 25 (10) 1984-1992

Year:: 2019
Type:: Manuscript
Funding:: NCTN
Endpoint:: Primary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: pmc-release

Note:

Methodological:: No
Biospecimen:: No
SDC:: No
Book Volume:: 9

Parents:: 2182 2248
Children:: None

Program:: OGC
Primary Committee:: Transplant
Sec. Committees:

Pharmas:: Otsuka
Grants:: U10CA180821, U10CA180882, U10CA180833, U10CA180838, U10CA180850, U10CA180854, UG1CA189819

Corr. Author:
Authors:: Ravi Vij Jennifer Le-Rademacher Kristina Laumann Vera Hars Kouros Owzar Tsiporah Shore Sumithira Vasu Amanda Cashen Luis Isola Thomas Shea Jr. Margarida DeMagalhaes-Silverman David Hurd Kenneth Meehan Frank Beardell Steven Devine

Networks:: CHRISTIANA, LAPS-MO011, LAPS-NC007, LAPS-NH012, LAPS-OH007, NC002, NY018, NY021

Study: CALGB-100801
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 2

Keywords:: Article